Clinical Trial Update: Testing Copanlisib as a Potential Targeted Treatment in Cancers With PIK3CA Mutations (MATCH-Subprotocol Z1F) [Phase 2]

View source ↗

Summary

Phase 2 MATCH subprotocol Z1F investigates copanlisib for cancers with PIK3CA mutations. Results (posted 2023-02-28) pertain to participants with advanced lymph…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lymphoma
• Multiple Myeloma
• Solid Malignant Neoplasm

Drugs mentioned

• Aliqopa (copanlisib)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Advanced Lymphoma, Advanced Malignant Solid Neoplasm | Phase 2 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2023-02-28